Upgrade to SI Premium - Free Trial

Bristol-Myers Squibb (BMY) Part 1 of Phase 3 CheckMate -227 Trial Met Primary Endpoint

July 24, 2019 4:48 PM
Bristol-Myers Squibb Company (NYSE: BMY) announced that Part 1a of the Phase 3 CheckMate -227 trial evaluating Opdivo® (nivolumab) plus ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Corporate News FDA

Next Articles